Glypressin

Glypressin is a prescription intravenous medication whose active ingredient is terlipressin acetate. It is supplied as a sterile solution for IV administration, marketed in the European Union. As a vasopressin analog, Glypressin acts as a V1 receptor agonist to produce vasoconstriction and lower portal pressure. It is used under medical supervision for specific hepatic and gastrointestinal conditions. The drug is available by prescription and requires dosing by a healthcare professional.

Glypressin is indicated for the management of conditions associated with elevated portal pressure and related bleeding risks. It is administered intravenously in a controlled clinical setting to achieve rapid hemodynamic effects.

- Control of acute esophageal variceal bleeding in patients with cirrhosis. - Reduction of portal hypertension during endoscopic or surgical procedures. - Adjunct therapy for hepatorenal syndrome to improve renal perfusion. - Management of bleeding associated with portal hypertensive gastropathy. - Temporary stabilization of hemodynamics in patients awaiting definitive treatment for portal hypertension.

The safety profile of Glypressin includes both frequent, mild reactions and less common, serious events that require immediate medical attention.

Common: - Headache or dizziness, often mild and transient during infusion. - Nausea, vomiting, or abdominal discomfort that usually resolves after treatment. - Transient elevation of blood pressure that is monitored and managed during administration. - Flushing, warmth, or mild pain at the intravenous infusion site.

Serious: - Severe hypertension or hypertensive crisis that may require antihypertensive therapy. - Cardiac arrhythmias, including tachycardia or atrial fibrillation, and possible myocardial ischemia. - Ischemic complications such as peripheral gangrene or tissue necrosis, especially with prolonged high-dose infusion.

When prescribing Glypressin, clinicians should evaluate patient history and monitor specific parameters to minimize risks associated with vasoconstriction and cardiovascular stress.

- Assess for uncontrolled hypertension or recent cardiovascular events before initiation. - Use caution in patients with coronary artery disease, heart failure, or arrhythmias. - Monitor blood pressure and heart rate continuously during infusion. - Adjust dose or discontinue if severe hypertension or ischemic signs develop. - Evaluate renal function, especially in patients with hepatorenal syndrome, as dose may need modification. - Avoid use in pregnancy unless benefits clearly outweigh potential risks.

Glypressin may interact with other agents that affect vascular tone, cardiac rhythm, or renal function, requiring careful review of concomitant medications.

Avoid: - Concurrent use of potent vasoconstrictors (e.g., norepinephrine, phenylephrine) that could exacerbate hypertension. - Combination with drugs that markedly increase systemic vascular resistance, such as ergot alkaloids.

Use with caution: - Beta‑blockers, which may mask tachycardia while hypertension persists. - Diuretics or nephrotoxic agents, given potential impact on renal perfusion. - Anticoagulants, as rapid hemodynamic changes can affect bleeding risk. - Inhaled or systemic vasodilators, which may counteract the intended effect.